First Drug-Coated Balloon Approved By FDA For Leg Blockages
The FDA today announced that it had approved  for use in the US the first drug-coated angioplasty balloon catheter to re-open blocked arteries in the thigh and knee (superficial femoral and popliteal arteries). The Lutonix 035 Drug Coated Balloon Percutaneous Transluminal Angioplasty Catheter (Lutonix DCB) is manufactured by CR Bard and has been available in Europe since 2012. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - October 10, 2014 Category: Pharmaceuticals Authors: Larry Husten Source Type: news

FDA approves first drug-coated angioplasty balloon catheter to treat vascular disease
The U.S. Food and Drug Administration today approved the Lutonix 035 Drug Coated Balloon Percutaneous Transluminal Angioplasty Catheter (Lutonix DCB). This is the first drug-coated balloon used to re-open arteries in the thigh (superficial femoral arteries) and knee (popliteal arteries) when narrowed or blocked as a result of peripheral artery disease (PAD). (Source: Food and Drug Administration)
Source: Food and Drug Administration - October 10, 2014 Category: American Health Source Type: news

TCT 2014: Medtronic's IN.PACT Admiral beats PTA in outcomes, costs
Medtronic unveils 1-year study results showing that its IN.PACT Admiral drug-coated balloon is clinically superior and more cost-effective than standard percutaneous transluminal angioplasty. Medtronic, TCT 2014News Well, Clinical Trials, Conference coverage, Minnesota, Peripheral Artery Disease, Transcatheter Cardiovascular Therapeutics symposium (TCT)read more (Source: Mass Device)
Source: Mass Device - September 16, 2014 Category: Medical Equipment Authors: Arezu Sarvestani Source Type: news

FDA OKs Medtronic's Euphora Non-Compliant Coronary Balloon Catheter
Coming just four months after its CE Mark European approval, the NC Euphora balloon has received the okay from the FDA for marketing in the United States. Non-compliant (NC) balloons are specifically designed to be used in post-stent dilatation, to ensure that the stent itself is fully expanded against the arterial wall. An under-expanded stent is associated with higher restenosis rates, as well as stent thrombosis, a phenomenon first described by Dr. Antonio Colombo in the early days of stenting. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - September 12, 2014 Category: Cardiology Source Type: news

Teleflex Receives FDA Clearance for 150 cm Length Arrow(R) GPSCath(R) Balloon Dilatation Catheters
PTA balloon catheters combine angioplasty with targeted injection system in a single device for use in below the knee procedures WAYNE, Pa.--(Healthcare Sales & Marketing Network)--Teleflex Incorporated (TFX), a leading global provider of medical device... Devices, Interventional, FDATeleflex, Arrow, GPSCath, Balloon Catheter, angioplasty (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - July 29, 2014 Category: Pharmaceuticals Source Type: news

Study Offers Reassurance About Newer Drug-Eluting Stents
Drug-eluting stents (DES) have been viewed as a great advance over earlier stents and balloon angioplasty because they result in many fewer cases of restenosis. But enthusiasm for the first generation of DES was somewhat curbed due to reports of late stent thrombosis (ST), a rare but very dangerous complication. Now findings from a large ongoing registry study provide some reassurance about the long-term safety of the new generation of drug-eluting stents in patients with heart attacks (STEMI). The results are published  in the Journal of the American College of Cardiology. (Source: Forbes.com Healthcare News)
Source: Forbes.com Healthcare News - July 1, 2014 Category: Pharmaceuticals Authors: Larry Husten Source Type: news

Peripheral Vascular Devices & Interventional Cardiology Market in...
ReportsnReports.com adds “North American Interventional Cardiology & Peripheral Vascular Devices Market by Angioplasty Balloon (Plain/Old, Cutting), Stent (Bioabsorbable, Drug-Eluting), Catheter...(PRWeb June 11, 2014)Read the full story at http://www.prweb.com/releases/North-america-industry/cardiology-peripheral/prweb11935323.htm (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - June 11, 2014 Category: Pharmaceuticals Source Type: news

Press Release: Medtronic Announces CE Mark and Launch of NC Euphora Coronary Balloon
Noncompliant Balloon Provides Superior Deliverability and Controlled Growth for Challenging Coronary Angioplasty Procedures. MedtronicNews Well, Regulatory/Clearance, Catheters, CE Mark, Minnesotaread more (Source: Mass Device)
Source: Mass Device - May 20, 2014 Category: Medical Equipment Authors: MassDevice Source Type: news

Medtronic Launches New Peripheral Angioplasty Catheter in Europe
Today Medtronic, Inc. (NYSE: MDT) announced the European launch of its latest product to address the problems of peripheral artery disease (PAD), the "TOTAL Across" crossing catheter, intended for use in the lower extremities, specifically those arterial blockages below the knee that often are the cause of critical limb ischemia. Today's announcement by Medtronic adds to their portfolio of peripheral devices, including the IN.PACT drug-eluting balloon, and several balloon catheters designed for use in challenging narrow below-the-knee blockages. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - February 13, 2014 Category: Cardiology Source Type: news

Medtronic Launches 'TOTAL Across' Crossing Catheter in Europe
New Peripheral Angioplasty Balloon Targets Challenging Lesions in Lower-Extremity, Including Below-the-Knee, Arteries Associated with Critical Limb Ischemia MINNEAPOLIS -- Feb. 13, 2014 --(Healthcare Sales & Marketing Network)-- Aligned with its commitm... Devices, Interventional, Product LaunchMedtronic, TOTAL across, crossing catheter, Angioplasty, Balloon catheter (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 13, 2014 Category: Pharmaceuticals Source Type: news

CCSVI surgery study
A randomised,double blind study of balloon angioplasty to treat CCSVI in people with MS found the procedure to be safe but "did not provide sustained improvement in MS patients. PR Web CCSVI - A to Z of MS (Source: Multiple Sclerosis Trust)
Source: Multiple Sclerosis Trust - November 22, 2013 Category: Neurology Source Type: news

Penile-Artery Angioplasty Gets Second Look for EDPenile-Artery Angioplasty Gets Second Look for ED
A small pilot trial is picking up where the ZEN trial of drug-eluting stents for ED left off, this time trying plain-old balloon angioplasty in the penile arteries. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 5, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Intact Vascular Announces Completion Of Enrollment Of The Tack Optimized Balloon Angioplasty (TOBA) Study
Intact Vascular, Inc., a developer of medical devices for minimally invasive peripheral vascular procedures, recently announced the completion of enrollment of the Tack Optimized Balloon Angioplasty (TOBA) study. (Source: Medical Design Online News)
Source: Medical Design Online News - October 4, 2013 Category: Medical Equipment Source Type: news

Heart attack death rates unchanged in spite of faster care at hospitals
Heart attack deaths have remained the same, even as hospital teams have gotten faster at treating heart attack patients with emergency angioplasty, according to a study in this week's New England Journal of Medicine. Hospitals across the country have successfully raced to reduce so-called door-to-balloon time, the time it takes patients arriving at hospitals suffering from a heart attack to be treated with angioplasty, to 90 minutes or less in the belief that it would save heart muscle and lives... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 7, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

Shorter waits for angioplasty do not lower death rates, study says
The average 'door-to-balloon' time for heart attack patients has dropped by 20%, but that has not translated into better survival rates, cardiologists say.An intense nationwide push to speed hospital treatment for heart attack patients has been a success, cutting by 20% the average time people waited before getting their clogged arteries opened between 2005 and 2009. (Source: L.A. Times - Health)
Source: L.A. Times - Health - September 5, 2013 Category: Consumer Health News Source Type: news

Shorter waits for angioplasty do not lower death rates, study says
The average 'door-to-balloon' time for heart attack patients has dropped by 20%, but that has not translated into better survival rates, cardiologists say.An intense nationwide push to speed hospital treatment for heart attack patients has been a success, cutting by 20% the average time people waited before getting their clogged arteries opened between 2005 and 2009. (Source: Los Angeles Times - Science)
Source: Los Angeles Times - Science - September 5, 2013 Category: Science Source Type: news

Vascular Connexins in Restenosis After Balloon Injury
Atherosclerosis is an arterial progressive disease characterized by accumulation of lipids, macrophages, T lymphocytes, and smooth muscle cells in large- and medium-sized arteries. Erosion and rupture of the atherosclerotic plaque may induce myocardial infarction and cerebrovascular accidents that are responsible for a large percentage of sudden death. Atherosclerosis is often treated by angioplasty generally followed by stent implantation. Although angioplasty and stent implantation are necessary for the survival of the patient, they induce a trauma in the vessel wall that favors a vascular reaction called restenosis and ...
Source: Springer protocols feed by Molecular Medicine - September 4, 2013 Category: Molecular Biology Source Type: news

Anticoagulant otamixaban does not reduce rate of ischemic events among certain patients undergoing PCI
Use of the novel anticoagulant otamixaban did not reduce ischemic events compared with unfractionated heparin plus eptifibatide but increased bleeding among patients with non-ST-segment elevation acute coronary syndromes undergoing a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), according to a study published by JAMA... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - September 3, 2013 Category: Consumer Health News Tags: Surgery Source Type: news

Anticoagulant does not reduce rate of ischemic events among certain patients undergoing PCI
(The JAMA Network Journals) Use of the novel anticoagulant otamixaban did not reduce ischemic events compared with unfractionated heparin plus eptifibatide but increased bleeding among patients with non-ST-segment elevation acute coronary syndromes undergoing a percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries), according to a study published by JAMA. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 1, 2013 Category: Global & Universal Source Type: news

Medtronic's Drug-Eluting Balloon Data for Peripheral Angioplasty Submitted to FDA
Medtronic, Inc. (NYSE: MDT) announced on Thursday that it had submitted its first pre-market approval (PMA) module to the U.S. Food and Drug Administration (FDA) for the IN.PACT Admiral drug-eluting balloon (DEB), to be used in the treatment of peripheral artery disease (PAD) in the superficial femoral artery. Medtronic reports that with submission of this data, it is on track to gain FDA approval in two years, which would make it the first drug-eluting balloon available in the U.S. for use in the treatment of peripheral disease. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - August 19, 2013 Category: Cardiology Source Type: news

Quitting smoking post-angioplasty tied to longer life
NEW YORK (Reuters Health) - People who quit smoking after a balloon angioplasty to improve blood flow to the heart live an average of two years longer than those who keep smoking, a new study suggests. (Source: Reuters: Health)
Source: Reuters: Health - August 1, 2013 Category: Consumer Health News Tags: healthNews Source Type: news

Quitting Smoking Post-Angioplasty Tied to Longer Life
People who quit smoking after a balloon angioplasty to improve blood flow to the heart live an average of two years longer than those who keep smoking, a new study suggests.Source: Reuters Health Related MedlinePlus Pages: Angioplasty, Coronary Artery Disease, Quitting Smoking (Source: MedlinePlus Health News)
Source: MedlinePlus Health News - August 1, 2013 Category: Consumer Health News Source Type: news

Dual Antiplatelet Therapy Following Coronary Stent Implantation Is Associated With Improved Outcomes
Emmanouil S. Brilakis, M.D., Ph.D., of the VA North Texas Health Care System and University of Texas Southwestern Medical Center at Dallas, and colleagues conducted a review of medical literature regarding optimal medical therapy after percutaneous coronary intervention (PCI; procedures such as balloon angioplasty or stent placement used to open narrowed coronary arteries). The researchers identified 91 studies for inclusion in the review... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - July 9, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

Drug-Eluting Balloon One Step Closer to FDA Submission as Medtronic Completes Enrollment for IN.PACT Study
Medtronic, Inc. (NYSE: MDT) announced today that its IN.PACT drug-eluting balloon clinical program had reached the enrollment needed to support submission to the FDA for approval to use this novel device in the treatment of peripheral disease, specifically blockages in the superficial femoral artery. Although the IN.PACT family of drug-eluting balloons (DEB) have been available in Europe for over four years, no drug-eluting balloons have been approved for use in the United States. (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - June 4, 2013 Category: Cardiology Source Type: news

Drug-coated Balloons May Provide New Method To Open Clogged Arteries
A new treatment method that combines the advantages of angioplasty balloons and drug-releasing stents, and offers fewer risks, has been examined as a way to open clogged arteries. The study, led my MIT researchers and published in the journal Circulation, outlines the new approach where a balloon is inflated in the artery for just a short period where it releases a drug that stops cells from building up and clogging the arteries over time... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 22, 2013 Category: Consumer Health News Tags: Cardiovascular / Cardiology Source Type: news

Ballooning After Carotid Stenting Not Best Choice? (CME/CE)
ORLANDO (MedPage Today) -- Balloon angioplasty after deployment of a carotid stent may increase stroke risk, a retrospective analysis of the CREST trial showed. (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - May 10, 2013 Category: Journals (General) Source Type: news

Heart Attack Response: Door-To-Balloon Times Can Be Lowered Using Process Improvement Strategies
While all heart attacks have the potential to be deadly, one type is referred to as the "widow maker" because of its high risk of death. A ST segment elevation myocardial infarction (STEMI) is a severe type of heart attack that occurs when a blockage in a coronary artery causes heart muscle to die; without prompt treatment risk of fatality increases dramatically. Coronary angioplasty, or percutaneous coronary intervention (PCI), is the most common emergency treatment for STEMI... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 1, 2013 Category: Consumer Health News Tags: Heart Disease Source Type: news

Stent Graft Maintains Dialysis Access (CME/CE)
NEW ORLEANS (MedPage Today) -- The Flair endovascular stent graft was better than balloon angioplasty at keeping hemodialysis access grafts open through 12 months, interim results of a randomized trial showed. (Source: MedPage Today Meeting Coverage)
Source: MedPage Today Meeting Coverage - April 16, 2013 Category: Journals (General) Source Type: news

Drug-Eluting Stents May Save Ischemic Limbs (CME/CE)
NEW ORLEANS (MedPage Today) -- Drug-eluting stents provide good outcomes for patients with critical limb ischemia in whom balloon angioplasty has failed, a single-center study showed. (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - April 15, 2013 Category: Cardiology Source Type: news

Drug-Eluting Balloon Angioplasty for in-Stent RestenosisDrug-Eluting Balloon Angioplasty for in-Stent Restenosis
What's the optimal treatment option for in-stent restenosis? Heart (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 4, 2013 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

Changing the face of Midaortic Syndrome treatment to save Sofia
The American Journal of Transplantation recently published a paper, documenting a first-of-its-kind treatment for midaortic syndrome, as performed by Khashayar Vakili, MD, of Boston Children’s Department of Surgery and Heung Bae Kim, MD, director of Boston Children’s Pediatric Transplant Center. In the following blog Marcus Groff, father of the patient described in the Journal of Transplantation, writes about his daughter’s revolutionary surgery at Boston Children’s. Sofia Two years ago my wife and I were anxiously waiting outside the NICU of our local hospital at four in the morning. Inside,...
Source: Thrive, Children's Hospital Boston - February 25, 2013 Category: Pediatrics Authors: Guest Blogger Tags: All posts Diseases & conditions Heart conditions Our patients’ stories Heung Bae Kim kidney transplant midaortic syndrome Midaortic Syndrome and Renovascular Hypertension (MAS/RVH) Program our patients' stories Pediatric Transplant Cen Source Type: news

AngioScore Launches New 100 mm Length AngioSculpt(R) Scoring Balloons For Treatment of Peripheral Artery Disease Below The Knee (BTK)
FREMONT, Calif.--(Healthcare Sales & Marketing Network)--AngioScore, Inc., a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease, today announced the launch of its new 100 mm length AngioSculpt PTA Scoring Balloon Ca... Devices, InterventionalAngioScore, AngioSculpt, Scoring Balloon Catheter, peripheral artery disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 25, 2013 Category: Pharmaceuticals Source Type: news

AngioScore Launches New 100 mm Length AngioSculpt Scoring Balloons For Treatment Of Peripheral Artery Disease Below The Knee (BTK)
AngioScore, Inc.,a developer of novel angioplasty catheters for use in the treatment of cardiovascular disease, recently announced the launch of its new 100 mm length AngioSculpt PTA Scoring Balloon Catheters for the treatment of peripheral artery disease (PAD) below the knee (BTK) (Source: Medical Design Online News)
Source: Medical Design Online News - January 25, 2013 Category: Medical Equipment Source Type: news

Medtronic Drug-Eluting Balloon Study Completes Enrollment
Medtronic, Inc. (NYSE: MDT), today announced completion of enrollment in IN.PACT SFA II, the U.S. arm of its clinical study for the IN.PACT Admiral drug-eluting balloon as a treatment for peripheral artery disease in the superficial femoral and proximal popliteal arteries (SFA and PPA). Results of IN.PACT SFA II will be combined with those from IN.PACT SFA I, which previously completed enrollment of 150 patients in Europe, to support a premarket approval (PMA) application to the U.S. Food and Drug Administration (FDA). (Source: News from Angioplasty.Org)
Source: News from Angioplasty.Org - January 23, 2013 Category: Cardiology Source Type: news

Drug-Eluting Balloon: Best Option for in-Stent Restenosis?Drug-Eluting Balloon: Best Option for in-Stent Restenosis?
The first meta-analysis to compare drug-eluting balloons with drug-eluting stents or plain angioplasty for in-stent restenosis indicates that the balloon comes out best. Guidelines should be changed accordingly, say the researchers, but others say this conclusion is premature. Heartwire (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 23, 2013 Category: Consumer Health News Tags: Cardiology News Source Type: news

Drug-eluting balloon: Best option for in-stent restenosis?
The first meta-analysis to compare drug-eluting balloons with drug-eluting stents or plain angioplasty for in-stent restenosis indicates that the balloon comes out best. Guidelines should be changed accordingly, say the researchers, but others say this conclusion is premature. (Source: theHeart.org)
Source: theHeart.org - January 22, 2013 Category: Cardiology Source Type: news